» Articles » PMID: 27723662

Pedunculopontine Nucleus Region Deep Brain Stimulation in Parkinson Disease: Surgical Anatomy and Terminology

Abstract

Several lines of evidence over the last few years have been important in ascertaining that the pedunculopontine nucleus (PPN) region could be considered as a potential target for deep brain stimulation (DBS) to treat freezing and other problems as part of a spectrum of gait disorders in Parkinson disease and other akinetic movement disorders. Since the introduction of PPN DBS, a variety of clinical studies have been published. Most indicate improvements in freezing and falls in patients who are severely affected by these problems. The results across patients, however, have been variable, perhaps reflecting patient selection, heterogeneity in target selection and differences in surgical methodology and stimulation settings. Here we outline both the accumulated knowledge and the domains of uncertainty in surgical anatomy and terminology. Specific topics were assigned to groups of experts, and this work was accumulated and reviewed by the executive committee of the working group. Areas of disagreement were discussed and modified accordingly until a consensus could be reached. We demonstrate that both the anatomy and the functional role of the PPN region need further study. The borders of the PPN and of adjacent nuclei differ when different brainstem atlases and atlas slices are compared. It is difficult to delineate precisely the PPN pars dissipata from the nucleus cuneiformis, as these structures partially overlap. This lack of clarity contributes to the difficulty in targeting and determining the exact localization of the electrodes implanted in patients with akinetic gait disorders. Future clinical studies need to consider these issues.

Citing Articles

Direct localization and delineation of human pedunculopontine nucleus based on a self-supervised magnetic resonance image super-resolution method.

Li J, Guan X, Wu Q, He C, Zhang W, Lin X Hum Brain Mapp. 2023; 44(9):3781-3794.

PMID: 37186095 PMC: 10203800. DOI: 10.1002/hbm.26311.


Cholinergic Modulation of Locomotor Circuits in Vertebrates.

Le Ray D, Bertrand S, Dubuc R Int J Mol Sci. 2022; 23(18).

PMID: 36142651 PMC: 9501616. DOI: 10.3390/ijms231810738.


Effect of MK-801, an antagonist of NMDA receptor in the pedunculopontine tegmental nucleus, on cardiovascular parameters in normotensive and hydralazine hypotensive rats.

Hosseiniravesh M, Hojati V, Khajavirad A, Shajiee H, Shafei M, Mohebbati R Iran J Basic Med Sci. 2022; 25(5):569-576.

PMID: 35911640 PMC: 9282751. DOI: 10.22038/IJBMS.2022.62431.13809.


Future Therapeutic Strategies for Freezing of Gait in Parkinson's Disease.

Cui C, Lewis S Front Hum Neurosci. 2021; 15:741918.

PMID: 34795568 PMC: 8592896. DOI: 10.3389/fnhum.2021.741918.


Optogenetic stimulation of glutamatergic neurons in the cuneiform nucleus controls locomotion in a mouse model of Parkinson's disease.

Fougere M, van der Zouwen C, Boutin J, Neszvecsko K, Sarret P, Ryczko D Proc Natl Acad Sci U S A. 2021; 118(43).

PMID: 34670837 PMC: 8639376. DOI: 10.1073/pnas.2110934118.


References
1.
Manaye K, Zweig R, Wu D, Hersh L, de Lacalle S, Saper C . Quantification of cholinergic and select non-cholinergic mesopontine neuronal populations in the human brain. Neuroscience. 1999; 89(3):759-70. DOI: 10.1016/s0306-4522(98)00380-7. View

2.
Teo C, Rasco L, Skinner R, Garcia-Rill E . Disinhibition of the sleep state-dependent p1 potential in Parkinson's disease-improvement after pallidotomy. Sleep Res Online. 2001; 1(1):62-70. View

3.
Honda T, Semba K . Serotonergic synaptic input to cholinergic neurons in the rat mesopontine tegmentum. Brain Res. 1994; 647(2):299-306. DOI: 10.1016/0006-8993(94)91329-3. View

4.
Karson C, Garcia-Rill E, Biedermann J, Mrak R, Husain M, Skinner R . The brain stem reticular formation in schizophrenia. Psychiatry Res. 1991; 40(1):31-48. DOI: 10.1016/0925-4927(91)90027-n. View

5.
Hirsch E, Graybiel A, Duyckaerts C . Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci U S A. 1987; 84(16):5976-80. PMC: 298986. DOI: 10.1073/pnas.84.16.5976. View